Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study

Foocharoen, Chingching; Chunlertrith, Kitti; Mairiang, Pisaln; Mahakkanukrauh, Ajanee; Suwannaroj, Siraphop; Namvijit, Suwassa; Wantha, Orathai; Nanagara, Ratanavadee

doi:10.1038/s41598-020-57636-0

Cited by 18 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our Delphi study showed that, according to the panellists, most SSc-ILD patients suffer from a number of comorbidities, such as gastroesophageal reflux disease (53.8%), fatigue (40.3%) or depression (22.6%). These results are consistent with the reports in the literature for SSc or SSc-ILD patients [ 32 – 34 ].…”

Section: Discussionsupporting

confidence: 93%

Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study

Davidsen

Miedema²,

Wuyts

et al. 2020

Adv Ther

View full text Add to dashboard Cite

Introduction: Systemic sclerosis (SSc) is a rare chronic autoimmune disease characterised by microvascular damage, immune dysregulation and fibrosis, affecting the skin, joints and internal organs. Interstitial lung disease (ILD) is frequently associated with systemic sclerosis (SSc-ILD), leading to a poor prognosis and a high mortality rate. The aim of the BUILDup study (BUrden of Interstitial Lung Disease Consensus Panel) was to investigate the overall disease management and to estimate the social and economic burden of SSc-ILD across 8 European countries. Methods: A modified Delphi method was used to obtain information on the management of SSc-ILD patients among 40 specialists (panellists) from 8 European countries. Average annual costs per patient and country were estimated by means of a direct cost-analysis study.

show abstract

Section: Discussionsupporting

confidence: 93%

Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study

Davidsen

Miedema²,

Wuyts

et al. 2020

Adv Ther

View full text Add to dashboard Cite

show abstract

“…The existence of delayed emptying of stomach may result in an insufficient response to treatment in these patients. In addition, Ren LH et al meta-analysis in 2016, showed that therapy of combination with prokinetics and PPIs improved the individual life quality by reducing the episodes of acid reflux episodes 20 . In this study, the mean score of FSSG was moderately in height (17.20 ± 8.40).…”

Section: Discussionmentioning

confidence: 99%

A Prospective Observational Study Combinition of Proton Pump Inhibitors with Prokinetics in Gerd

Mushtaq¹,

Adeel²,

Hussain³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: Gastroesophageal reflux disease (GERD), a fairly common ailment that has a negative influence on quality of life. 30- 40% of patients with GERD have an insufficient response to standard PPIs therapy. For subjects resistant to this PPI therapy, double the PPI dosage or switch to different PPIs, which may not be ideal. So, combination therapy with prokinetic agent will significantly improve GERD symptoms. Study Design: A prospective observational study. Place and Duration: In the Department of Medicine, Faisalabad Medical University, Faisalabad from May 2022 to July 2022. Material and methods: 130 patients with suggestive symptoms of GERD were included to evaluate overlap between GERD and delayed gastric emptying and to forecast the necessity for therapy in combination with prokinetic drugs using the Frequency Scale for the Symptoms of GERD (FSSG) score. Results: 17.20 ± 8.40 was the mean total score of FSSG. Of the 130 subjects, 106 (81.54%) patients have GERD symptoms with an overall FSSG score >8. 7.43 ± 4.08 was the mean reflux score, and 9.40 ± 5.30 was the mean dysmotility score. In this analysis, patients with GERD symptoms had high score of FSSG, the symptoms of dysmotility appeared to be the main symptom than acid reflux. Conclusions: Based on this analysis results, combination therapy with prokinetic and PPIs in the subgroups of subjects with high scores of FSSG improved GERD symptoms. Keywords: Dysmotility score, delayed gastric emptying, GERD and Reflux score.

show abstract

“…The therapeutic approaches based on PPIs and prokinetic medications effectively reduce GERD manifestations while improving gastric emptying, esophageal sphincter pressure, and intestinal peristalsis. [50][51][52] Endoscopic dilatation and continuous administration are preferred therapies for systematically managing and preventing esophageal strictures in systemic sclerosis. EGD surveillance with biopsy is recommended in Barrett's esophagus, and treatment includes endoscopic ablation or resection of dysplastic epithelium using photochemical, thermal, or radio ablation energy.…”

Section: Esophagusmentioning

confidence: 99%

Gastrointestinal involvement in systemic sclerosis: An updated review

et al. 2022

View full text Add to dashboard Cite

The gastrointestinal tract (GI) is the second most affected organ system in individuals suffering from systemic/localized scleroderma (SSc) or localized scleroderma. SSc can affect any part of the GI, between the oral cavity and anorectum. The annual incidence of SSc in the United States is estimated to be 19.3 cases per million adults, with the highest incidence reported in people aged 44 to 55. Females are 5 times more likely than males to suffer from SSc. Morbidity and mortality rates associated with SSc are predominantly elevated among patients with GI manifestations. Esophageal and intestinal manifestations impact 90% and 40% to 70% of patients with systemic scleroderma, respectively. SSc patients are known to suffer from small bowel hypomotility and small intestinal bacterial overgrowth, which cause malabsorption and malnutrition, ultimately contributing to the 50% mortality rate. Fecal incontinence is a common symptom of SSc that can lead to depression. SSc patients may suffer from gastrointestinal complications that can negatively impact their quality of life on a daily basis. Multidisciplinary approaches are necessary for systematically managing gastrointestinal complications associated with SSc. A prospective study should focus on developing targeted therapies to improve recovery patterns and prognosis in cases of SSc. This article summarizes the epidemiology, commonly reported clinical manifestations, complications, and available treatments for treating GI pathology in SSc patients.

show abstract

Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study

Cited by 18 publications

References 41 publications

Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study

Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study

A Prospective Observational Study Combinition of Proton Pump Inhibitors with Prokinetics in Gerd

Gastrointestinal involvement in systemic sclerosis: An updated review

Contact Info

Product

Resources

About